文献速递免疫规划

通过新型病毒样颗粒设计增强神经氨酸酶免疫原性

Enhancing NA immunogenicity through novel VLP designs.
PubMed 文献 · Vaccine · 2024-08-27

研究旨在通过调整疫苗中血凝素与神经氨酸酶比例及延长神经氨酸酶茎部两种策略增强神经氨酸酶免疫原性。将甲型流感病毒A/California/04/2009株H1N1糖蛋白展示于HIV-1 gag病毒样颗粒,用不同启动子获得HA:NA约1:1至2:1比例,并插入15个氨基酸延长茎部,制备6种病毒样颗粒。小鼠接种两剂低剂量(0.3 μg)即诱生强效神经氨酸酶抑制抗体且不损害抗HA应答,证明两种策略可行。

要点

  • 调整HA:NA比例至约1:1至2:1可增强神经氨酸酶免疫原性。
  • 延长神经氨酸酶茎部旨在提高表位可及性。
  • 小鼠接种两剂0.3 μg病毒样颗粒即诱生强效神经氨酸酶抑制抗体。

核心结论

  • 结果表明两种策略在保留HA免疫原性的同时改善NA免疫原性,可作为未来流感疫苗候选。

研究设计与样本

  • 将甲型流感病毒A/California/04/2009株H1N1糖蛋白展示于HIV-1 gag病毒样颗粒,用杆状病毒昆虫细胞表达系统及两种启动子偏倚表面糖蛋白数量,并插入A-New York/61/2012株15个氨基酸延长NA茎部,制备并纯化6种病毒样颗粒,在小鼠模型中测试。

主要发现

  • 使用不同启动子使HA:NA比例达1:1至2:1,约为野生型甲型流感病毒(HA:NA比例3:1至5:1)中NA量的两至三倍。
  • 小鼠接种两剂低剂量(0.3 μg)H1N1病毒样颗粒即诱生强效神经氨酸酶抑制抗体,且不损害抗HA应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current influenza virus vaccines poorly display key neuraminidase (NA) epitopes and do not robustly induce NA-reactive antibodies; instead, they focus on the induction of hemagglutinin (HA)-reactive antibodies. Next-generation influenza vaccines should be optimized in order to activate NA-reactive B cells and to induce a broadly cross-reactive and protective antibody response. We aimed at enhancing the immunogenicity of the NA on vaccines by two strategies: (i) modifying the HA:NA ratio of the vaccine preparation and (ii) exposing epitopes on the lateral surface or beneath the head of the NA by extending the NA stalk. The H1N1 glycoproteins from the influenza virus A/California/04/2009 strain were displayed on human immunodeficiency virus 1 (HIV-1) gag-based virus-like particles (VLP). Using the baculovirus insect cell expression system, we biased the quantity of surface glycoproteins employing two different promoters, the very late baculovirus p10 promoter and the early and late gp64 promoter. This led to a 1:1 to 2:1 HA:NA ratio, which was approximately double or triple the amount of NA as present on the wild-type influenza A virus (HA:NA ratio 3:1 to 5:1). Furthermore, by insertion of 15 amino acids from the A-New York/61/2012 strain (NY12) which prolongates the NA stalk (NA long stalk; NA-LS), we intended to improve the accessibility of the NA. Six different types of VLPs were produced and purified using a platform downstream process based on Capto-Core 700™ followed by Capto-Heparin™ affinity chromatography combined with ultracentrifugation. These VLPs were then tested in a mouse model. Robust titers of antibodies that inhibit the neuraminidase activity were elicited even after vaccination with two low doses (0.3 μg) of the H1N1 VLPs without compromising the anti-HA responses. In conclusion, our results demonstrate the feasibility of the two developed strategies to retain HA immunogenicity and improve NA immunogenicity as a future influenza vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guzman Ruiz L, Zollner AM, Hoxie I, et al. Enhancing NA immunogenicity through novel VLP designs. Vaccine. 2024. PMID: 39197219. doi:10.1016/j.vaccine.2024.126270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。